Navigation Links
BIO Ventures for Global Health Announces Management Changes
Date:6/25/2009

Christopher D. Earl Resigning as CEO

Board member Melinda Moree named interim leader

WASHINGTON, June 25 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, Ph.D., will resign from BVGH, effective July 9, 2009. Melinda Moree, Ph.D., a member of the board since BVGH's inception, will serve as interim CEO until a permanent replacement is hired.

"I've been galvanized by my experience in global health and honored to have the opportunity to contribute," says Dr. Earl. "I look forward to continuing to work at the interface of public health, science, and entrepreneurship."

"Chris's imagination and expertise have enabled BVGH to demonstrate the integral role the biotechnology industry can play in addressing the urgent medical needs of developing countries," says Robert B. Chess, Chairman of BVGH. "From promoting new financial incentives that reward companies for investing in global health R&D, to creating Innovation Maps that define a path toward making new breakthrough therapies, we thank Chris for his commitment and contributions. In particular, we are pleased that BVGH secured a three-year, $7 million renewal of funding from the Bill & Melinda Gates Foundation under Chris' leadership."

Melinda Moree, Ph.D., previously served as Executive Director for the PATH Malaria Vaccine Initiative, a $50 million/year Product Development Partnership funded by the Bill & Melinda Gates Foundation. She also served as Vice President, Global Health Services, Applied Strategies, supporting global, regional, and national health organizations in their mission to improve human health worldwide.

"BVGH has had an impact through initiatives launched by Chris such as last year's Partnering for Global Health Forum that brought together biotechnology executives and global health innovators," says Jim Greenwood, President and CEO of the Biotechnology Industry Organization and a member of the BVGH Board. "We look forward to continued success through Melinda's knowledge of BVGH and depth of experience in forging partnerships between the private and public sectors to keep BVGH operating at a high level."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for infectious diseases of the developing world. BVGH breaks down barriers that hinder industry initiatives in global health product development. We foster collaboration among stakeholders in industry, philanthropy, academia, and government, and we catalyze industry investment through the creation of new market-based incentives. For more information please visit www.bvgh.org.


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):